New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Laura Blair
Medication Adherence

David Linetsky
Patient Activation

Matthew Durham
Omnidynamic Marketing

Mike Viscel
Increasing Engagement

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Thomas Shea
Programmatic Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Frank X. Powers
Healthcare Challenger Brands

Anil Bhaskar
Unified Customer Experience